Knightscope, Inc. (NASDAQ: KSCP) is making a broader case than “robots on patrol.” With record second-quarter revenue, an expanding national client base, new AI-driven security capabilities and an integrated model that joins autonomous machines with trained human professionals, the company is positioning itself…
Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21
Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…
Seven Boson Group’s expansion within the Google Cloud partner ecosystem and its increasingly defined sovereign-AI strategy offer a bullish picture of a company aiming to participate in a more mature phase of the artificial-intelligence buildout. The premise is compelling: as AI moves…
The biotechnology market has a habit of demanding patience right up until it abruptly decides to reward it. Moderna, Inc. (NASDAQ: MRNA) recently reminded investors of that rule as enthusiasm around its personalized melanoma-vaccine program with Merck & Co., Inc. (NYSE: MRK)…
For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…
The AI Trade Is Growing Up
Artificial intelligence has spent the last several years behaving like a fashionable restaurant with a six-month waiting list: expensive, crowded, and occasionally more admired for the bill than the meal. The next phase, however, may be…
In the bustling digital amphitheater of Tribe Public’s latest CEO Presentation, the question of the hour was as sharp as it was timely: “Is the beaten down biotech sector the smartest bet in today’s volatile market?” With a flourish of slides and…
